|
|
|
|
|
|
|
|
|
15.01.26 - 14:03
|
Collegium to Present Four Real-World Data Posters at APSARD 2026 Annual Conference (GlobeNewswire EN)
|
|
|
STOUGHTON, Mass., Jan. 15, 2026 (GLOBE NEWSWIRE) -- Collegium Pharmaceutical, Inc. (Nasdaq: COLL) today announced it will have four poster presentations highlighting real-world data from its ADHD product, Jornay PM (methylphenidate HCl), a central nervous system (CNS) stimulant indicated for the treatment of attention deficit hyperactivity disorder (ADHD) in people 6 years of age and older and developed using a novel delayed-release extended-release delivery platform, at the American Professional Society of ADHD and Related Disorders (APSARD) Annual Conference being held from January 15-18, 2026, in San Diego, California....
|
|
|
|
|
|
|
23.12.25 - 13:33
|
Dyne Therapeutics Appoints Vikram Karnani to Board of Directors (GlobeNewswire EN)
|
|
|
WALTHAM, Mass., Dec. 23, 2025 (GLOBE NEWSWIRE) -- Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional improvement for people living with genetically driven neuromuscular diseases, today announced the appointment of Vikram Karnani to its Board of Directors. Mr. Karnani brings extensive commercial and executive leadership experience in rare disease and biopharmaceuticals, serving as the current chief executive officer of Collegium Pharmaceutical and having spent nearly a decade leading several lines of business and functions at Horizon Therapeutics....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
